Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide capsules plus low-dose dexamethasone for relapsed/refractory multiple myeloma
CTR20202125Phase 3Completed
- Sponsor
- Yangtze River Pharmaceutical Group
- Start
- Dec 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pomalidomide, dexamethasone in multiple myeloma (MM), sponsored by Yangtze River Pharmaceutical Group. Started Dec 2020; status: completed.
02
Drugs
pomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20202125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202125.